Bjørn-Eivind Kirsebom, PhD, University Hospital of North Norway, Tromsø, Norway, discusses brain-derived (BD) tau as a biomarker in Alzheimer’s disease (AD). BD-tau has emerged recently as an AD-specific marker of neurodegeneration. Unlike NfL, BD-tau uniquely reflects the extent of neurodegeneration in patients with AD, showing high accuracy to differentiate AD from other dementias. A recent study revealed faster cognitive decline and higher atrophy rates in p-tau181-positive and BD-tau positive-cases compared to p-tau181-positive and BD-tau-negative cases. Furthermore, BD-tau showed no or much weaker correlations with age, renal function, other comorbidities/risk factors and race/ethnicity, compared with other blood biomarkers. This interview took place at the AD/PD 2024 congress in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
